Establishment and Validation of a Gene Signature-Based Prognostic Model to Improve Survival Prediction in Adrenocortical Carcinoma Patients

Figure 6

Mutational analysis in different risk groups: (a and b) oncoplots for ACC samples with low- and high-risk scores were generated, respectively; (c) with a threshold of  < 0.05 using Fisher’s exact test, a differentially mutated gene named CTNNB1 was detected between the two risk cohorts; (d) significant higher tumor mutation burden (TMB) was observed in ACC samples with higher risk scores; and (e and f) more co-occurrence mutations were observed in the low-RS cohort, and more mutually exclusive mutations were observed in the high-RS cohort.

(a)

(b)

(c)

(d)

(e)

(f)